KR101692707B1 - 가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸 - Google Patents

가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸 Download PDF

Info

Publication number
KR101692707B1
KR101692707B1 KR1020157005961A KR20157005961A KR101692707B1 KR 101692707 B1 KR101692707 B1 KR 101692707B1 KR 1020157005961 A KR1020157005961 A KR 1020157005961A KR 20157005961 A KR20157005961 A KR 20157005961A KR 101692707 B1 KR101692707 B1 KR 101692707B1
Authority
KR
South Korea
Prior art keywords
compound
electrospray
mmol
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157005961A
Other languages
English (en)
Korean (ko)
Other versions
KR20150048765A (ko
Inventor
제로드 버넷 브렌너먼
존 데이비드 진
마이클 디. 로우
크리스토퍼 로날드 사르코
에드워드 에스. 타스버
중화 장
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20150048765A publication Critical patent/KR20150048765A/ko
Application granted granted Critical
Publication of KR101692707B1 publication Critical patent/KR101692707B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020157005961A 2012-09-07 2013-09-03 가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸 Active KR101692707B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697899P 2012-09-07 2012-09-07
US61/697,899 2012-09-07
PCT/US2013/057826 WO2014039434A1 (en) 2012-09-07 2013-09-03 Alkoxy pyrazoles as soluble guanylate cyclase activators

Publications (2)

Publication Number Publication Date
KR20150048765A KR20150048765A (ko) 2015-05-07
KR101692707B1 true KR101692707B1 (ko) 2017-01-04

Family

ID=49170904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157005961A Active KR101692707B1 (ko) 2012-09-07 2013-09-03 가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸

Country Status (37)

Country Link
US (2) US8906904B2 (enExample)
EP (1) EP2892891B1 (enExample)
JP (1) JP5970134B2 (enExample)
KR (1) KR101692707B1 (enExample)
CN (1) CN104619695B (enExample)
AP (1) AP2015008231A0 (enExample)
AR (1) AR092869A1 (enExample)
AU (1) AU2013312931B2 (enExample)
BR (1) BR112015004529B1 (enExample)
CA (1) CA2880494C (enExample)
CL (2) CL2015000255A1 (enExample)
CY (1) CY1122610T1 (enExample)
DK (1) DK2892891T3 (enExample)
EA (1) EA027244B1 (enExample)
EC (1) ECSP15012804A (enExample)
ES (1) ES2748798T3 (enExample)
GE (1) GEP20176631B (enExample)
HR (1) HRP20191755T1 (enExample)
HU (1) HUE046996T2 (enExample)
IL (1) IL236987A (enExample)
LT (1) LT2892891T (enExample)
MA (1) MA37891B1 (enExample)
MD (1) MD4425C1 (enExample)
MX (1) MX338887B (enExample)
NZ (1) NZ703989A (enExample)
PE (1) PE20151001A1 (enExample)
PH (1) PH12015500457A1 (enExample)
PL (1) PL2892891T3 (enExample)
PT (1) PT2892891T (enExample)
RS (1) RS59394B1 (enExample)
SG (2) SG10201510668UA (enExample)
SI (1) SI2892891T1 (enExample)
TN (1) TN2015000054A1 (enExample)
TW (1) TWI586661B (enExample)
UA (1) UA115881C2 (enExample)
UY (1) UY35012A (enExample)
WO (1) WO2014039434A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2892891T3 (da) * 2012-09-07 2019-10-14 Boehringer Ingelheim Int Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EA032972B1 (ru) * 2014-07-22 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
JP2018537488A (ja) 2015-12-18 2018-12-20 ノバルティス アーゲー インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020011804A1 (en) * 2018-07-12 2020-01-16 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
KR20220084347A (ko) * 2019-10-18 2022-06-21 에프엠씨 코포레이션 5-브로모-2-(3-클로로-피리딘-2-일)-2h-피라졸-3-카복실산의 제조 방법
CN112079712B (zh) * 2020-09-18 2022-12-13 江苏美迪克化学品有限公司 一种对乙烯基水杨酸的制备方法
AR124297A1 (es) * 2020-12-10 2023-03-15 Bayer Ag Ácidos pirazol piperidin carboxílicos sustituidos
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023183213A1 (en) 2022-03-21 2023-09-28 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating portal hypertension
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024097316A1 (en) 2022-11-04 2024-05-10 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating systemic sclerosis
CN120359219A (zh) 2022-12-09 2025-07-22 勃林格殷格翰国际有限公司 Sgc活化剂的固体形式
WO2025036839A1 (en) 2023-08-16 2025-02-20 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
JP2010538065A (ja) 2007-09-06 2010-12-09 メルク・シャープ・エンド・ドーム・コーポレイション 可溶性グアニレートシクラーゼ活性化因子
WO2011095534A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
MXPA03004308A (es) 2000-11-22 2003-08-19 Visx Inc Dispositivo de colocacion, accionado por la temperatura, para elementos opticos no lineales.
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
EP2144605A1 (en) 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
EP2207541B1 (en) * 2007-10-05 2014-10-29 Sanofi-Aventis Deutschland GmbH Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA32967B1 (fr) 2009-01-17 2012-01-02 Bayer Schering Pharma Ag Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
ES2549979T3 (es) * 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
DK2892891T3 (da) * 2012-09-07 2019-10-14 Boehringer Ingelheim Int Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538065A (ja) 2007-09-06 2010-12-09 メルク・シャープ・エンド・ドーム・コーポレイション 可溶性グアニレートシクラーゼ活性化因子
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2011095534A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Also Published As

Publication number Publication date
HRP20191755T1 (hr) 2019-12-27
LT2892891T (lt) 2020-01-27
AU2013312931A1 (en) 2015-02-05
CL2015000255A1 (es) 2015-05-29
CA2880494A1 (en) 2014-03-13
AP2015008231A0 (en) 2015-01-31
TW201422607A (zh) 2014-06-16
CY1122610T1 (el) 2021-03-12
EA027244B1 (ru) 2017-07-31
PH12015500457B1 (en) 2015-04-20
EA201500298A1 (ru) 2015-08-31
JP5970134B2 (ja) 2016-08-17
CN104619695A (zh) 2015-05-13
UA115881C2 (uk) 2018-01-10
KR20150048765A (ko) 2015-05-07
AU2013312931B2 (en) 2017-06-22
GEP20176631B (en) 2017-02-27
TN2015000054A1 (en) 2016-06-29
SG10201510668UA (en) 2016-01-28
HUE046996T2 (hu) 2020-04-28
USRE46886E1 (en) 2018-06-05
MX338887B (es) 2016-05-04
ES2748798T3 (es) 2020-03-18
IL236987A (en) 2017-02-28
US20140073629A1 (en) 2014-03-13
CL2015000562A1 (es) 2015-06-12
MX2015002807A (es) 2015-05-15
CA2880494C (en) 2021-09-21
DK2892891T3 (da) 2019-10-14
HK1210164A1 (en) 2016-04-15
WO2014039434A1 (en) 2014-03-13
CN104619695B (zh) 2018-04-10
UY35012A (es) 2014-03-31
BR112015004529A2 (pt) 2017-07-04
RS59394B1 (sr) 2019-11-29
PE20151001A1 (es) 2015-07-15
MA37891A1 (fr) 2018-01-31
SG11201500861QA (en) 2015-04-29
JP2015527394A (ja) 2015-09-17
PT2892891T (pt) 2019-11-05
MA37891B1 (fr) 2018-05-31
PH12015500457A1 (en) 2015-04-20
MD4425C1 (ro) 2017-01-31
EP2892891B1 (en) 2019-07-31
ECSP15012804A (es) 2015-12-31
BR112015004529A8 (pt) 2019-08-27
MD4425B1 (ro) 2016-06-30
US8906904B2 (en) 2014-12-09
PL2892891T3 (pl) 2020-01-31
MD20150019A2 (ro) 2015-07-31
SI2892891T1 (sl) 2019-11-29
AR092869A1 (es) 2015-05-06
TWI586661B (zh) 2017-06-11
BR112015004529B1 (pt) 2022-06-21
EP2892891A1 (en) 2015-07-15
NZ703989A (en) 2017-04-28

Similar Documents

Publication Publication Date Title
KR101692707B1 (ko) 가용성 구아닐레이트 사이클라제 활성제로서의 알콕시 피라졸
JP6602840B2 (ja) 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸
EP2683710B1 (en) Soluble guanylate cyclase activators
CN102365277B (zh) Jun n-末端激酶抑制剂
JP5252404B2 (ja) ピラジン化合物、その使用及び調製方法
KR20230118142A (ko) 심부전 치료용 rxfp1 조절제로서의 4-(2-플루오로-4-메톡시-5-3-(((1-메틸시클로부틸)메틸)카바모일)바이시클로[2.2.1]헵탄-2-일)카바모일)페녹시)-1-메틸시클로헥산-1-카복실산유도체 및 유사 화합물
AU2016372048A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
HK1210164B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
TW202028199A (zh) 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物
HK40003699A (en) Amide derivative inhibitor and preparation method and application thereof
HK1167655B (en) Inhibitors of jun n-terminal kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160118

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160714

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20161209

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20161229

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20161230

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20201218

Start annual number: 5

End annual number: 5